Related Experiment Videos
Review: advances in monoclonal antibody tumour targeting
C Kosmas1, H Linardou, A A Epenetos
1Department of Clinical Oncology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Abstract:
Since the breakthrough in producing monoclonal antibodies was achieved, this new tool has opened up numerous avenues in basic science and clinical investigation. In the area of oncology, monoclonal antibodies were initially seen as offering new hopes of a cure and many investigations in the last decade therefore focused on applying these reagents in tumour diagnosis and therapy. The results to date have been less encouraging and have served as a basis for understanding current limitations in the application of monoclonal antibodies and designing future strategies to overcome these problems. Advances in molecular biology now offer the possibility of better understanding tumour antigens and of constructing recombinant antibody fragments and fusion proteins with novel effector functions. Furthermore, advances in chelate and isotope chemistry have enabled the use of more potent and stable radiolabelled immunoconjugates. Better understanding of tumour biology and the mechanisms of tumour escape from current therapeutic approaches in opening up the intriguing possibility of combining monoclonal antibody-based therapy with chemotherapy, radiotherapy, and biological response modifiers.
Insights
Monoclonal antibodies show promise in oncology but face limitations. Future strategies involve advanced molecular biology and improved immunoconjugates for better tumor targeting and combination therapies.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) revolutionized basic science and clinical research, particularly in oncology.
- Initial optimism for mAbs in cancer diagnosis and therapy has been tempered by limited success, highlighting current challenges.
Purpose of the Study:
- To review the limitations of current monoclonal antibody applications in oncology.
- To explore future strategies for enhancing mAb efficacy in cancer treatment.
Main Methods:
- Review of recent advances in molecular biology for understanding tumor antigens.
- Integration of novel recombinant antibody fragments and fusion proteins.
- Application of improved chelate and isotope chemistry for radiolabeled immunoconjugates.
Main Results:
- Advances enable better comprehension of tumor antigens and engineering of novel antibody formats.
- Enhanced immunoconjugates offer improved potency and stability for targeted delivery.
- New insights into tumor biology and escape mechanisms facilitate combination therapy design.
Conclusions:
- Overcoming current limitations requires innovative approaches in antibody engineering and drug delivery.
- Future cancer therapies may involve combining monoclonal antibodies with chemotherapy, radiotherapy, and biological response modifiers for synergistic effects.